These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3403218)

  • 1. Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.
    Rainero I; Gilli M; De Gennaro T; Chiadò I; Delsedime M; Riccio A; Bergamasco B
    Ital J Neurol Sci; 1988 Jun; 9(3):255-9. PubMed ID: 3403218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1998 Jun; 54(4):303-8. PubMed ID: 9696954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Clin Neurol Neurosurg; 1989; 91(4):303-9. PubMed ID: 2555090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
    Hutton JT; Albrecht JW; Román GC; Kopetzky MT
    Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
    Contin M; Riva R; Martinelli P; Procaccianti G; Baruzzi A
    Clin Neuropharmacol; 1989 Feb; 12(1):75-81. PubMed ID: 2713868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
    Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
    Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
    Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T
    Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    Clin Neuropharmacol; 2012; 35(2):67-72. PubMed ID: 22377973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
    Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.